You are here
Small molecule programmes focused on the development of inhibitors of novel cancer targets and pathways are available for co-development and/or licensing.
CRUK has developed a potent, selective and orally bioavailable series of small molecules inhibiting glutaminase (GLS), with superior developability.Read more
AZD3965 is a Phase 2 ready, first-in-class oral and highly selective inhibitor of MCT-1 that has shown promising signs of efficacy in early phase clinical trials in DLBCL.Read more
We have developed first-in-class IKKα selective compounds with in vivo data showing strong inhibition of tumour growth.Read more